Observational Program Neo-Penotran® Forte

Bayer

Status: Completed

Conditions: Vaginal Candidiasis; Trichomonal Vaginitis; Bacterial Vaginosis

Treatments: Drug: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)

Study type: Observational

Funder types: Industry

Identifiers

NCT01335373

NP1010KZ (Other Identifier)

15511

Details and patient eligibility

About

Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection.

Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.

Enrollment: 13,024 patients

Sex: Female

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.

Exclusion criteria

• Presence of contraindications according to package insert.

Trial design

13,024 participants in 1 patient group

Group 1

Treatment:

Drug: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)